SH3TC2 and cancer: The expression levels of SH3TC2 in the 27 types of cancers are shown in Figure 1A. The results showed that the expression of SH3TC2 was significantly higher in several cancers compared to normal tissues, including kidney renal papillary cell carcinoma (KIRP) (p < 0.01), COAD (p < 0.0001), stomach adenocarcinoma (STAD) (p < 0.0001), kidney renal clear cell carcinoma (KIRC) (p < 0.0001), skin cutaneous melanoma (SKCM) (p < 0.0001), bladder urothelial carcinoma (BLCA) (p < 0.0001), READ (p < 0.0001), pancreatic adenocarcinoma (PAAD) (p < 0.0001), and cholangiocarcinoma (CHOL) (p < 0.001).